在抗甲状腺药物治疗后,格雷夫斯病复发的预测模型:回顾性多中心队列研究
Omar El Kawkgi1, David Toro-Tobon2, Freddy J K Toloza3
1Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Mayo Clinic, Rochester, Minnesota; Department of Endocrinology, Mayo Clinic Health System, Eau Claire, Wisconsin.
概括
在抗甲状腺药物治疗后预测格雷夫斯病复发是至关重要的. 使用年龄和FT4水平的新模型可以帮助预测在停止治疗一年内复发的风险.
科学领域:
- 内分泌学 在内分泌学.
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 格雷夫斯病 (GD) 是一种常见的自身免疫性疾病,导致甲状腺功能增强症.
- 抗甲状腺药物 (ATD) 是主要的治疗方法,但停药后的复发很常见.
- 预测复发对于个性化治疗策略至关重要.
研究的目的:
- 确定在停止抗甲状腺药物治疗后预测格雷夫斯病复发的因素.
- 使用常规的临床参数,在治疗后的第一年内开发GD复发风险的预测模型.
主要方法:
- 使用来自美国3个学术中心的电子健康记录进行观察性队列研究.
- 用ATDs治疗的GD患者的人口和临床特征的分析.
- 开发和验证GD复发的预测模型和名录.
主要成果:
- 总共有523名患者被纳入;211人停止了ATD,其中142人用于模型开发.
- 在停止ATD治疗的患者中,37.44%的患者在一年内出现复发.
- 增加年龄 (每十年) 和较高的基线自由甲状腺素 (FT4) 水平是复发的显著预测因素.
结论:
- 使用基线年龄和FT4水平的实用模型可以预测ATD停止后Graves病复发风险.
- 这种模型有助于GD患者的初始治疗决策.
- 需要进一步的研究来完善预测模型并确定额外的复发因素.
相关概念视频
Synthesis and Regulation of Thyroid Hormones
4.2K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.2K
Myasthenia Gravis: Diagnostic Tests
642
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
642
Desensitization and Tachyphylaxis
1.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.5K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
26
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
26


